Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Blood Cancer
  •  Targeted Therapy
  •  Kidney Cancer
  •  Immunology
  •  Immunotherapy
  •  Carcinomas
  •  Radiation Therapy
  •  Brain and Spinal Cord Cancer

Abstract

Citation: Clin Oncol. 2017;2(1):1178.DOI: 10.25107/2474-1663.1178

Clinical Prognostic Factors are better Outcome Predictors than Molecular Factors in Glioblastoma

Samprón N, Undabeitia J, Torres-Bayona S, Aldaz P, Carrasco-Garcia E, Arrazola M, Villanua J, Egaña L, Caballero MC, Etxegoien I, Bollar A, Querejeta A, Armendáriz M, Torres P, Pardo E, Liceaga G, Urtasun M, Ruiz I, Matheu A and Urculo E

Department of Neurosurgery, Hospital Universitario Donostia, Spain
Instituto Oncológico, Spain
Neurooncology Tumor Board, Hospital Universitario Donostia, Spain
Cellular Oncology Research Group, Spain
Institute of Radiology, Spain
Department of Medical Oncology, Hospital Universitario Donostia, Spain
Department of Pathology, Hospital Universitario Donostia, Spain
Department of Radiology, Hospital Universitario Donostia, Spain
Department of Radiation Oncology, Hospital Universitario Donostia, Spain
Department of Pharmacology, Hospital Universitario Donostia, Spain
Department of Neurology, Hospital Universitario Donostia, Spain

*Correspondance to: Sampron N 

 PDF  Full Text Research Article | Open Access

Abstract:

The World Health Organization (WHO) classification of central nervous system tumors 2016 classifies glioblastoma in the highest grade of aggressiveness. Nowadays, all the treatment for this type of tumor remains palliative. Surgical resection is the primary treatment. Radiotherapy and chemotherapy have been shown to prolong survival, although most patients die within two years. Due to the poor prognosis and discreet effectiveness of the treatment, the patients’ quality of life throughout the whole process should be the main concern. Over the last 15 years, several clinical and molecular prognostic markers have been identified, but their impact varies within different studies. In this work, we have done a follow-up of a clinical cohort of patients with glioblastoma and have identified that age, functional status and number of surgeries is the main predictors of survival.

Keywords:

Glioblastoma; Oncology; Survival; Temozolomide; Neurosurgery; Clinical information; Prognostic factors

Cite the Article:

Samprón N, Undabeitia J, Torres- Bayona S, Aldaz P, Carrasco-Garcia E, Arrazola M, et al. Clinical Prognostic Factors are better Outcome Predictors than Molecular Factors in Glioblastoma. Clin Oncol. 2017;2: 1178.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Thromboxane-Prostanoid Receptor Signaling as Potential Therapy for Pulmonary Fibrosis
 PDF  Full Text
Enhanced Recovery after Surgery Protocol for Patients Undergoing Radical Cystectomy
 Abstract  PDF  Full Text
View More...